Gilead Sciences

GILD · NASDAQ

$156.51+$3.44 (+2.25%)TodayMarket closed · Oct 20, 7:57 PM ET

Prev close $153.07

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada for PrEP, and others. The company also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. The company has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The company operates in over 35 countries worldwide.

Employees: 17,000
Headquarters: Foster City, California
Listed: Jan 22, 1992
Sector: Health Care
Industry: Biotechnology
Website: gilead.com

Leadership

Gilead Sciences executives
Name	Title	Since	Age
Daniel O'Day	—	2019	60
Andrew Dickinson	—	—	55
Keeley Wettan	—	—	—
Erin Burkhart	—	—	46
Dietmar Berger	—	—	62
Johanna Mercier	—	—	55
Anthony Welters	—	—	70
Jacqueline Barton	—	—	72
Jeffrey Bluestone	—	—	72
Sandra Horning	—	—	76
Kelly Kramer	—	—	57
Ted Love	—	—	66
Harish Manwani	—	—	71
Javier Rodriguez	—	—	54

Revenue by product and region

Fiscal year ended Dec 31, 2025: $29.44B total revenue

By product

Product sales$28.91B98.2%
Royalty, contract and other revenues$527.00M1.8%

By region

U.S.$20.88B70.9%
Europe$5.06B17.2%
Rest of World$3.50B11.9%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Gilead Sciences suppliers and customers
Company	Relationship	Country	Correlation
SAP SE SAPGF	Supplier	—	0.78
Vir Biotechnology VIR	Supplier and customer	US	0.77
Biocartis Group BCART.BR	Supplier	BE	0.77
Nektar Therapeutics NKTR	Supplier and customer	US	0.76
Instem INS.L	Supplier	GB	0.74
Nurix Therapeutics NRIX	Supplier and customer	US	0.72
Scholar Rock Holding SRRK	Supplier	US	0.69
Precision BioSciences, Inc. DTIL	Supplier	US	0.69
Xencor, Inc. XNCR	Supplier	US	0.68
Gritstone bio GRTS	Supplier and customer	US	0.65

Similar companies

Companies in the same industry as Gilead Sciences

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.